DDInter1042 DDInter583
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Donepezil {u} (Compound) resembles {v} (Compound) Doxazosin
Donepezil {u} (Compound) resembles {v} (Compound) Moexipril
Donepezil {u} (Compound) treats {v} (Disease) Alzheimer's disease
Donepezil {u} (Compound) binds {v} (Gene) CYP2D6
Donepezil {u} (Compound) upregulates {v} (Gene) MAPKAPK5
Donepezil {u} (Compound) downregulates {v} (Gene) CCNB2
Donepezil {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Donepezil (Compound) resembles Doxazosin (Compound)
Donepezil (Compound) resembles Moexipril (Compound)
Donepezil (Compound) treats Alzheimer's disease (Disease)
Donepezil (Compound) binds CYP2D6 (Gene)
Donepezil (Compound) upregulates MAPKAPK5 (Gene)
Donepezil (Compound) downregulates CCNB2 (Gene)
Donepezil (Compound) causes Abdominal pain upper (Side Effect)
Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin